Thermo Fisher Scientific (TMO) Projected to Post Quarterly Earnings on Thursday

Thermo Fisher Scientific (NYSE:TMO) is expected to be posting its Q4 2025 results before the market opens on Thursday, January 29th. Analysts expect Thermo Fisher Scientific to post earnings of $6.44 per share and revenue of $11.9519 billion for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, January 29, 2026 at 8:30 AM ET.

Thermo Fisher Scientific Trading Down 0.3%

Thermo Fisher Scientific stock opened at $624.77 on Wednesday. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $643.99. The business has a 50-day simple moving average of $593.04 and a two-hundred day simple moving average of $535.10. The company has a market cap of $234.73 billion, a P/E ratio of 36.09, a P/E/G ratio of 4.12 and a beta of 0.91. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share buyback plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the transaction, the executive vice president owned 18,731 shares in the company, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Frederick M. Lowery sold 6,912 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total value of $4,022,369.28. Following the sale, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,360,731.98. This trade represents a 32.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 124,517 shares of company stock valued at $72,363,568 over the last quarter. 0.33% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Hedge funds have recently modified their holdings of the company. Brighton Jones LLC increased its stake in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the period. Darwin Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at $170,000. Raymond James Financial Inc. raised its position in Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after acquiring an additional 53,542 shares during the period. Finally, California State Teachers Retirement System grew its position in shares of Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after purchasing an additional 2,262 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. UBS Group lifted their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research report on Thursday, October 23rd. Evercore ISI reiterated an “outperform” rating and issued a $650.00 target price on shares of Thermo Fisher Scientific in a report on Monday, January 5th. Leerink Partners upped their target price on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Finally, Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $625.47.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.